NASDAQ:RLMD

Relmada Therapeutics Inc’s latest rating changes from various analysts
Daniel Torres
Relmada Therapeutics Inc’s recently made public that its Chief Executive Officer TRAVERSA SERGIO acquired Company’s shares for reported $86735.0 on ...





